Telomir-1: the next breakthrough in anti-aging therapy

Can you imagine? Just by taking a pill every morning you can live significantly longer. Preclinical studies show the potential of a new small molecule drug called Telomer-1. Read Hot Science below.

Longevity market, while very young, is exploding. And investment firms focusing on that market are multiplying. Another recent investment is highlighted in the Hot Investments below.

‍

Hot Science

Telomir Pharmaceuticals, Inc. is advancing the field of longevity by developing Telomir-1, a groundbreaking small molecule aimed at lengthening telomeres, the protective caps of DNA, to potentially treat age-related diseases. This innovative approach, which can potentially stimulate cell rejuvenation and extend lifespan, was showcased recently by Telomir at the Global Longevity Federation Conference in Las Vegas.

Telomere attrition is one of the cellular hallmarks of aging. Therefore, Telomir research is an important contribution to the healthspan sciences. Immorta Bio is taking a different approach to solving the same issue. We use patients' own cells, reprogrammed to a young state. These cells naturally possess elongated telomeres and address some other hallmarks of aging. We believe that approach offers a more intrinsic and holistic solution in the fight for healthy longevity.

‍

Hot Investments

Hevolution's $50 million investment in Aeovian Pharmaceuticals marks a significant leap in aging therapies, focusing on selective mTORC1 inhibitors. This Berkeley-based biotech's pioneering platform could lead to breakthrough treatments for aging-related diseases, including tuberous sclerosis complex and refractory epilepsy. By targeting the mTORC1 pathway, crucial in cell growth and aging, Aeovian's research offers hope for extending healthspan and tackling prevalent neurological conditions, addressing critical global medical needs.

Hevolution Foundation is one of a few investment organizations and firms, launched lately, that specifically focused on the scientific longevity industry. This growing interest in Immorta Bio’s projected market supports our belief that we are in the right place at the right time.

‍

Longevity Shorts

• Alliance for Longevity Initiatives recent event in DC underscored importance of government funding and regulatory support to the research, development, and commercialization of biotech healthspan solutions.
  

• Immorta Bio President and CSO, Dr. Thomas Ichim, presented at RGE Murray Seminar Series at University of Western Ontario, showcasing Immorta Bio's advances in Mesenchymal Stem Cells research.
  

• The fourth Cognitive Aging Summit, convened recently in Bethesda, Maryland, uniting leading researchers to explore advancements in understanding cognitive changes with age, emphasizing strategies for longevity and precision brain therapeutics.

‍

Term of the Day

iPSC: Induced Pluripotent Stem Cells are generated from adult cells reprogrammed into a pluripotent state, capable of developing into any cell type. This breakthrough enables the production of patient-specific cells for regenerative medicine, disease modeling, and drug testing. In anti-aging and longevity research, iPSCs offer promising avenues for understanding the mechanisms of aging, developing rejuvenative therapies, and creating cell replacement strategies to mitigate age-related decline and extend healthspan.

‍

Boris Reznik, PhD
Chairman